Effect of ascorbic acid prophylaxis on the frequency of chromosome aberrations, urine mutagenicity and nucleolus test in workers occupationally exposed to cytostatic drugs.
The genetic risk of workers occupationally exposed to a series of newly developed cytostatic drugs and the presumed antimutagenic potential of ascorbic acid (AA) were studied in a group of 38 chemical laboratory personnel examined for chromosome aberrations in lymphocytes, urine mutagenicity and nucleolar RNA activity before and after a 6-month prophylactic administration of AA at daily doses of 1 g for 5 days a week. Chromosome aberration tests revealed elevated aberrant cell (AB.C) rates both prior to and after AA supplementation (3.9% and 3.65% of AB.C., respectively). These values were significantly higher than those found in 18 non-exposed matching controls (1.05% of AB.C.). Tests for mutagenic activity in the urine of drug-exposed workers revealed 64% positive urine samples prior to vitaminization and 60% positive urine specimens after it; positive urine samples in the group of controls accounted for 21% of samples. In the nucleolus test, numbers of inactivated micronuclei in the exposed were initially higher than those of controls (33.4% versus 24.3%), but dropped to 20.5% after AA supplementation. These findings show that AA prophylaxis alone cannot substantially reduce the hazards associated with exposure to anti-cancer drugs.
Rössner
P
P
Institute of Hygiene and Epidemiology, Prague, Czechoslovakia.
Cerná
M
M
Pokorná
D
D
Hájek
V
V
Petr
J
J
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002466:Cell Nucleolus / Q000502:physiology / Q000648:ultrastructure; D002869:Chromosome Aberrations; D006801:Humans; D009152:Mutagenicity Tests; D009153:Mutagens / Q000652:urine*; D009784:Occupational Diseases / Q000235:genetics* / Q000517:prevention & control / Q000652:urine
D000970:Antineoplastic Agents; D009153:Mutagens; D001205:Ascorbic Acid